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Abstract
Background Up to 25% of colorectal cancers present with bowel obstruction. Metal stents (MS) can provide a bridge to surgery
by relieving obstruction and allowing the subject’s condition to improve pre-operatively.
Methods Hospital Episode Statistics (HES) is a database of all NHS funded secondary care episodes in England. Subjects
admitted with bowel obstruction secondary to colorectal cancer without metastases were identified and subdivided into two
groups: MS insertion prior to surgery and surgery only. Due to demographic differences between the groups, propensity score
matching was used to analyse procedural outcomes, mortality and readmission within 30 days in left-sided cancers based upon
age, sex and Charlson co-morbidity score.
Results Over 10 years, 4571 subjects were identified; 401 received a MS and 4170 underwent surgery only. Median age of MS
subjects was 71 (IQR 62–79) years; 226 (56.4%) were male. Median age of surgery-only subjects was 73 (64–81); 2165 (51.9%)
were male. Following propensity matching 375 MS and 375 surgery-only subjects remained; MS had fewer readmissions within
30 days (28 (7.5%) versus 44 (11.7%), p = 0.047), fewer respiratory complications (< 6 (< 1.5%) versus 28 (7.5%), p < 0.001),
lower stoma rates (49 (13.1%) versus 159 (42.4%), p < 0.001) and higher rates of laparoscopic surgery (154 (41.1%) versus 25
(6.7%), p < 0.001). Mortality was lower in the MS group at 30 days (7 (1.9%) versus 33 (8.8%), p < 0.001) and 1 year (37 (9.9%)
versus 71 (19.0%), p < 0.001).
Conclusions In subjects presenting with obstructing colorectal cancer outcomes including respiratory complications, readmission
and mortality appear to be better in subjects undergoing MS as a bridge to surgery compared to surgery alone.
Keywords Colorectal cancer . Bowel obstruction . Colonic stent . Colorectal surgery
Introduction
Colorectal cancer is the third most common form of cancer
internationally [1]. A significant proportion of colorectal can-
cer subjects are diagnosed when they present with colorectal
obstruction. This group represents between 16 and 25% of
new colorectal cancer diagnoses [2, 3]. These subjects often
have advanced malignancies, poor nutritional status and usu-
ally have significantly deranged physiology at presentation.
The primary treatment goal is to relieve the obstruction, usu-
ally through emergency surgery. However, such operations
carry significant risks, and recently published outcome data
suggest that in-hospital mortality is as high as 14% [4].
Outcomes are significantly better for non-emergency or elec-
tive resections with mortality rates of 0.7% and 3.7% reported
for laparoscopic and open procedures, respectively [4].
Subjects undergoing an elective surgical procedure can be
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00384-019-03302-5) contains supplementary
material, which is available to authorized users.
* Nigel J Trudgill
nigel.trudgill@nhs.net
1 Department of Gastroenterology, Sandwell and West Birmingham
Hospitals NHS Trust, Birmingham, UK
2 Department of Health Informatics, University Hospital Birmingham
NHS Foundation Trust, Birmingham, UK
3 Institute of Cancer and Genomic Science, University of Birmingham,
Birmingham, UK
International Journal of Colorectal Disease (2019) 34:1295–1302
https://doi.org/10.1007/s00384-019-03302-5
optimised prior to the operation. There is also more opportu-
nity to undertake detailed staging and consult with a multi-
disciplinary team (MDT).
Colorectal metal stents (MS) represent an alternative to
emergency surgery, relieving obstruction without the need
for immediate surgical resection. This has the potential to
significantly reduce the risk of resectional surgery in subjects
presenting with obstruction. However, colorectal MS are not
commonly used in subjects presenting with obstruction, espe-
cially in curable disease [5]. A meta-analysis of randomised
control trials including a total of 273 subjects from five trials
of whom 136 underwent a MS insertion prior to surgical treat-
ment for their underlying malignancy. Although no survival
benefit was found, it was demonstrated that MS subjects had
fewer complications and lower stoma rates [6]. It has been
suggested that although surgeons are very willing to place
MS in subjects with metastatic colorectal cancer, they are less
comfortable with such an approach, incorporating delayed
surgery, in potentially curable disease [7].
The aim of this study was to utilise national administrative
data from Hospital Episode Statistics (HES) to study a large
cohort of subjects undergoingMS insertion followed by semi-
elective curative resection in comparison with subjects under-
going immediate resectional surgery for bowel obstruction
due to colorectal cancer.
Methods
Hospital episode statistics
The HES database is the administrative record of all episodes
of care provided by the National Health Service (NHS) within
England under the National Health Service [8]. A unique iden-
tification code allows episodes of care to be linked together for
individual subjects. Information recorded within an episode
includes subject demographic, diagnostic (International clas-
sification of diseases 10 (ICD10)) and procedural data (Office
of Population Census and Surveys Classification of
Interventions and Procedures, version 4 (OPCS4) codes) and
can be linked to the Office of National Statistics (ONS) for
mortality data.
Inclusion and exclusion criteria
Subjects were included if they had an ICD10 diagnosis code
between January 2006 and December 2015 for an emergency
admission with bowel obstruction (Appendix 1). A diagnosis
code for colon cancerwithin 12months prior or up to 3months
after the episode of obstruction was also required (Appendix
2). A co-existing OPCS4 code for colorectal resection
(Appendix 3) at the same time or within the subsequent
12 months to the colon cancer diagnosis was also mandatory.
Subjects were included in the MS group if an OPCS4 code
for colorectal MS (appendix 4) was present within 4 weeks of
being admitted with obstruction. If no MS code was present,
they were included in the surgery-only group.
Subjects were excluded if there was a code for metastatic
disease (except lymph node metastasis) prior to surgery to
ensure only those treated with curative intent were included
(Appendix 5). Subjects were also excluded if they were under
18 years of age at the time of presenting with obstruction, if
they were resident outside of England or of no fixed abode, as
follow-up may occur outside of England and not be captured.
Subjects with missing age or sex and those with a death date
recorded prior to initial presentation were excluded, as this
information is used to generate the unique HES patient ID.
Subjects undergoing MS followed by resection more than
12 months later were also excluded.
Data validation
All subjects undergoing a MS insertion for colon cancer were
identified over a 3-year period (January 2012–December
2014) at Sandwell and West Birmingham NHS trust from
multiple sources including endoscopy reporting software, the
radiology reporting system and individual operator logs. This
was then compared to the number of MS for colon cancer in
HES for the same time period for the same provider to assess
the accuracy of HES data extraction for MS in colorectal
cancer.
The rate of stent failure in the MS group, defined as re-
quirement for surgical resection during the same admission as
stent insertion, was compared to published studies [9].
Data analysis
Time to surgery was calculated from the date of emergency
admission with obstruction to subsequent resectional surgery.
When multiple colorectal surgeries were found, the surgery
closest to the admission with obstruction was included with
further procedures considered as re-operations.
Demographic data extraction included gender, age, ethnic-
ity and deprivation quintile based on the Indices of Multiple
Deprivation (2010) (1 being the most deprived, 5 the least
deprived). The type of resection including stoma formation
and if the surgical resection was during the same admission
as the presentation with obstruction were also extracted from
HES. A Charlson co-morbidity score was also calculated at
the time of obstruction; however, cancer was excluded from
this score. This scoring system has previously been validated
in HES [10, 11]. Length of stay data was collected to allow a
comparison of bed days between different treatment
strategies.
Following resection codes for complications (Appendix 6)
were sought in HES within 30 days of discharge and the 30-
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day emergency re-admission rate. The proportion of open ver-
sus laparoscopic surgery and stoma formation was also calcu-
lated. Cases were also linked to ONSmortality data to provide
7- and 30-day mortality.
Statistical analysis
Statistical analysis was performed using STATA version 14
[12]. Univariable analyses were performed utilising Chi-
squared and Fishers’ exact test where appropriate for categor-
ical variables, and Mann Whitney tests for non-parametric
data items. P values of < 0.05 were considered statistically
significant. Values of 5 or fewer are suppressed and expressed
as < 6 in line with national guidelines on the publication of
HES data.
Preliminary comparison of unmatched MS and surgery-
only groups revealed significant demographic differences,
and therefore, propensity score matching was performed.
The user written program BPSMATCH2^ in STATA was
used to pair each MS subject to a surgery-only subject
[13]. Subjects with similar propensity scores were selected
using 1:1 nearest-neighbour matching with calliper width
of 0.001 and no replacement. Each pair was used once and
unpaired cases were excluded from further analysis.
Subjects with a transverse or non-extended right
hemicolectomy were excluded from propensity score
matching as they were unlikely to be managed with a
MS. The matching model included gender, age at obstruc-
tion, resection type and Charlson co-morbidity score. Once
matched, the remaining included subject outcomes, includ-
ing mortality and complications, were compared using
univariable analysis. Kaplan-Meier graph of matched co-
horts was constructed for 1-year survival and compared
using log-rank test.
Results
Data validation
Between 2012 and the end of 2014 at Sandwell and West
Birmingham Hospitals NHS Trust, 27 MS were inserted for
obstruction secondary to cancer. Over the same time period,
25 were coded within HES as undergoing MS for obstruction
secondary to colorectal cancer, giving a 92.6% concordance.
The CREST study (randomised phase III study of
stenting as a bridge to surgery in obstructing colorectal
cancer—results of the UK ColoRectal Endoscopic
Stenting Trial), currently published in abstract form only,
provides further opportunity for validation [9]. Stenting
success was reported in the trial as 82% compared to
86.5% in the current study. Similarly, the largest meta-
analysis reported technically successful stent placement
in 88.5% in 1061 subjects [14].
Subject demographics (un-matched)
There were 4571 subjects who met the inclusion criteria, of
whom 401 underwent MS insertion, from an initial group of
32,039 (793 MS) who presented with bowel obstruction be-
tween 2006 and 2015 secondary to colorectal cancer. Reasons
for exclusions are shown in Fig. 1.
The study subject demographics are described in Table 1.
In the whole study population, the surgery-only group was
numerically older (73(IQR 64–81 versus 71 (63–79) years)
and less likely to have no co-morbidities recorded (64.6%
versus 69.8%, p = 0.005). There appeared to be no statistically
significant differences in sex, deprivation or ethnicity.
The most common initial surgical resection in the MS
group was rectal operations (174, 43.4%) or left
hemicolectomy (119, 29.7%). Subjects undergoing surgery
only were most likely to have a right hemicolectomy (1808,
43.4%) followed by rectal surgery (913, 21.9%) (p < 0.001).
Propensity matched analysis
Following propensity matching 375 MS were paired to 375
surgery-only subjects for analysis. Univariable comparison of
Charlson scores (p = 0.960), age (p = 0.997), gender (p =
0.941) and resection type (p = 1.0) no longer revealed a statis-
tical difference between the groups.
Subgroup demographics of propensity-matched subjects
undergoing conservative management (no resection or
stent during index admission) for bowel obstruction dem-
onstrate that this cohort has less co-morbidity compared to
those undergoing stent placement or surgery only (full data
presented in appendix 7).
Procedure outcomes following propensity matching
The MS procedure appeared to have a similarly high de-
gree of technical success in the matched cohort with 330
(88.0%) subjects not requiring a resection during the initial
admission with obstruction (Table 2). In the surgery-only
group, 104 (27.7%) subjects did not require surgical resec-
tion at the time of presentation with obstruction. This is
likely to represent successful conservative management.
Median time to resection in the MS group following pre-
sentation with obstruction was 32 days and 3 days in the
surgery-only group. Subjects were more likely to have a
laparoscopic resection following MS (41.1%) compared to
the surgery-only group (6.7%, p < 0.001). MS subjects
were also less likely to be left with a stoma (13.1%) than
surgery-only group subjects (42.4%, p < 0.001).
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Mortality and complications after resection following
propensity matching
Univariable analyses following propensity matching demon-
strated that subjects in the MS group had lower 30 -day mor-
tality compared to the surgery-only group (7 (1.9%) versus 33
(8.8%), p < 0.001) and lower 1-year mortality (37 (9.9%) ver-
sus 71 (18.9%)) (Table 2). The difference in mortality at 1 year
is shown in a Kaplan-Meier chart (Fig. 2).
At 30 days, readmission rates were higher following sur-
gery only compared to MS (7.5% versus 11.7%, p = 0.047).
Respiratory complications were also significantly lower in the
MS group (p < 0.001) (Table 3).
Discussion
Following propensity score matching of MS and surgery-only
subjects to control for differences in co-morbidity score and
age between the groups, subjects receiving a bridgingMS had
significantly lower 30-day mortality (1.9%) when compared
to their surgery-only counterparts (8.8%). Consequently, 1-
year mortality was also lower for MS subjects (9.9%) com-
pared to the surgery group (18.9%).
The most recent meta-analysis of colorectal MS as a bridge
to surgery, including 136 bridging stents, reported that 30-day
mortality after MS was 5.9% compared to 7.3% in the
surgery-only group [7]. A larger meta-analysis from 2004 of
non-randomised studies included 407 bridging stents and re-
ported 0.58% 30-day mortality, albeit without a comparator
surgical group without a MS [6]. In ESCO, a multicentre
Italian randomised control study, 60-day mortality was report-
ed as 7.1% and 5% for MS and surgery-only groups, respec-
tively [13]. A preliminary report of the CReST trial describes
5.3% and 4.4% 30-day mortality for MS and surgery-only
groups, respectively [9]. The present study differs from previ-
ous studies in that our sample population is larger, including
401 MS compared to 136 in the latest meta-analysis, 56 in
ESCO and 246 total randomised subjects (actual stent number
not yet reported) in CReST. Furthermore, there are significant
methodological differences, CReST and ESCO both report
shorter times to surgery within 4 weeks and a median of
5 days, respectively. By comparison, median time to surgery
was 32 (IQR 20–46) days in the present study. This is a
Fig. 1 Study flow chart
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significant difference, as one of the main arguments for using
bridging MS is to facilitate a period of medical stabilisation
prior to surgery. Shortening the time between resection and
MS insertion will potentially reduce the benefit ofMS in com-
parison with proceeding straight to surgery for obstruction.
Hospital Episode Statistics data provides a powerful tool to
examine subject outcomes, but has a number of limitations, in
particular, a lack of data regarding tumour stage (such as
TNM), illness severity markers, treatment intention and other
data important to outcomes. However, trials of MS in left-
Table 1 Study subject
demographics in the whole study
population and after propensity
matching
Variables n (%) Whole study population After propensity matching
Surgery only
(n = 4170)
Metal stent
(n = 401)
p value Surgery only
(n = 375)
Metal stent
(n = 375)
p
value
Age in years
≤ 29 32 (0.8) – 0.051 – – 0.997
30–39 74 (1.8) 10 (2.5) 7 (1.9) 9 (2.4)
40–49 188 (4.5) 21 (5.2) 20 (5.3) 20 (5.3)
50–59 450 (10.8) 48 (12.0) 45 (12) 46 (12.3)
60–69 886 (21.3) 95 (23.7) 90 (24) 90 (24)
70–79 1345 (32.3) 139 (34.7) 128 (34.1) 128 (34.1)
≥ 80 1195 (28.7) 88 (22.0) 85 (22.7) 82 (21.9)
Sex
Male 2165 (51.9) 226 (56.36) 0.089 211 (56.3) 212 (56.5) 0.941
Female 2005 (48.1) 175 (43.64) 164 (43.7) 163 (43.5)
Deprivation
Quintile 1 > 720 (> 17.3) 70 (17.5) 0.963 66 (17.6) 63 (16.8) 0.994
Quintile 2 798 (19.1) 81 (20.2) 77 (20.5) 76 (20.3)
Quintile 3 884 (21.2) 82 (20.5) 76 (20.3) 74 (19.7)
Quintile 4 876 (21.0) 87 (21.7) 80 (21.3) 84 (22.4)
Quintile 5 888 (21.3) 81 (20.2) 76 (20.3) 78 (20.8)
Unknown (< 0.001)a 0 (0)
Ethnicity
White 3637 (87.2) 352 (87.8) 0.761 311 (82.9) 328 (87.5) 0.486
Asian 64 (1.5) a a a
Black 76 (1.8) 7 (1.75) 10 (2.7) 7 (1.9)
Mixed 16 (0.4) a a a
Other 59 (1.4) a 8 (2.1) a
Unknown 318 (7.6) 31 (7.7) 39 (10.4) 30 (8)
Charlson co-morbidity score
0 2695 (64.6) 280 (69.8) 0.005 272 (72.5) 272 (72.5) 0.96
1–4 690 (16.6) 72 (18.0) 63 (16.8) 65 (17.3)
5+ 785 (18.8) 49 (12.2) 40 (10.7) 38 (10.1)
Surgical resection type
Right
Hemicolectomy
1808 (43.4) > 5 (> 1.2)a < 0.001 b b 0.987
Rectal operation 913 (21. 9) 174 (43.4) 172 (45.8) 172 (45.9)
Extended right
hemicolectomy
749 (18.0) 34 (8.5) 32 (8.5) 34 (9.1)
Left
Hemicolectomy
339 (8.1) 119 (29.7) 109 (29.1) 110 (29. 3)
Sigmoid
colectomy
316 (7.6) 61 (15.2) 62 (16.5) 59 (15.7)
Transverse
Colectomy
45 (1.1) a b b
a Indicates that the figure is < 6. If a single figure is censured, another will be marked as B>^ reflecting a value up
to 5 points higher than that stated, to ensure that the censured figure cannot be calculated
b Excluded from propensity-matched groups
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sided obstruction require a potentially unwell or unstable pa-
tient group and surveys have demonstrated clinician reluc-
tance to use MS in the scenario of potentially curable colorec-
tal cancer [7]. It is therefore not surprising that multicentre
randomised studies of bridging MS have struggled to recruit
subjects. An analysis using HES data is therefore a pragmatic
method of analysing a large dataset to address questions
concerning outcomes of bridging MS. Having used the HES
Table 2 Surgical outcomes following colon cancer resection in the whole study population and after propensity matching
Variables Whole study population After propensity-matching
Surgery only
(n = 4170)
Bridging metal
(n = 401)
p value Surgery only
(n = 375)
Bridging stent
(n = 375)
p value
Obstruction episode length of stay (days) 14 (8–23) 6 (4–10) N/A 13 (8–23) 6 (4–10) N/A
Time to MS insertion (days) 2 (1–3) N/A 2 (1–3) N/A
Time to resection (days) 2 (1–9) 32 (20–48) < 0.001 3 (1–14) 32(20–46) < 0.001
Length of stay for resection (days) 12 (7–20) 7 (5–13) < 0.001 12 (8–22) 7 (5–13) < 0.001
Stoma required
No 3173 (76.1) 349 (87.0) < 0.001 216 (57.6) 326 (86.9) < 0.001
Yes 997 (23.9) 52 (13.0) 159 (42.4) 49 (13.1)
Resection method
Conversion to open 108 (2.6) 33 (8.2) < 0.001 9 (2.4) 32 (8.5) < 0.001
Laparoscopic 300 (7.2) 166 (41.4) 25 (6.7) 154 (41.1)
Open 3762 (90.2) 202 (50.4) 341 (90.9) 189 (50.4)
Resection during admission for obstruction
No 840 (20.1) 352 (87. 8) < 0.001 104 (27.7) 330 (88) < 0.001
Yes 3330 (79.9) 49 (12.2) 271 (72.3) 45 (12)
Death within 30 days of resection
No 3778 (90.6) 394 (98.3) < 0.001 342 (91.2) 368 (98.1) < 0.001
Yes 392 (9.4) 7 (1.8) 33 (8.8) 7 (1.9)
Death within 1 year of resection
No 3186 (76.4) 361 (90.0) < 0.001 304 (81.1) 338 (90.1) < 0.001
Yes 984 (23.6) 40 (10.0) 71 (18.9) 37 (9.9)
Re-admission within 30 days of resection
No 3632 (87.1) 371 (92.5) 0.002 331 (88.3) 347 (92.5) 0.047
Yes 538 (12.9) 30 (7.5) 44 (11.7) 28 (7.5)
Fig. 2 Propensity matched
Kaplan-Meier curves with 95%
confidence intervals for 1-year
survival post-resection for colon
cancer
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coding to exclude any subject with metastatic disease and by
only including those undergoing a resection intended to be
curative, study subjects should only represent a narrow spec-
trum of tumour stages. Future studies would benefit from
linkage to the national cancer registry, data including staging
data, although this is not currently available under the terms of
access to HES.
A systematic source of selection bias which could not be
entirely corrected for derives from those subjects who are at
higher operative risk. If surgery is performed initially, then
they will be included in the present study. Should a MS be
placed with bridging intent in such subjects, once the higher
operative risk is fully assessed, the treatment plan may change
to not include resection. Therefore in this analysis, the MS
group will exclude some very high-risk subjects who do not
proceed to resection compared to the surgery-only group.
Selective-survival bias will similarly impact on the results
in that any subject who undergoes an intended bridging MS
insertion but does not survive to resection will not be included
in the MS group. Selection bias will be reduced by utilising
propensity matched analysis. This method gives a propensity
score to each subject based upon age at obstruction, gender,
type of surgery and Charlson co-morbidity score. Subjects can
then be matched carefully based on these parameters. In non-
randomised studies with large numerical and constitutional
discrepancies between participant numbers per cohort, this
technique allows close matching of the study groups.
Furthermore, those without a suitable match are excluded.
This will therefore reduce the potential for selection bias de-
scribed above.
As a non-randomised study subject selection for bridging
MS was by the treating physician. Therefore, there will be a
potential bias towards those subjects in whom aMS is expect-
ed to give a good outcome. Propensity matching allows us to
ameliorate this bias based upon measureable variables, but as
noted above, some important variables, such as physiological
status and tumour stage, are not available within HES.
Data validation represents a key challenge. Stent placement
is a relatively uncommon event on an individual provider
basis. It is even less commonwhen used as a bridge to surgery.
Therefore, local validation focused on all stents inserted for
colorectal cancer. The use of national data sources to support
validation is not feasible, as there are no comparable data sets
including only subjects presenting with obstruction. Clinical
Table 3 Complications within
30 days of colon cancer resection
in the whole study population and
after propensity matching
Whole study population After propensity-matching
Surgery only
(n = 4170)
Metal stent
(n = 401)
p value Surgery only
(n = 375)
Metal stent
(n = 375)
p value
Acute kidney injury
No 4004 (96.0) 394 (98.3) 0.025 362 (96.5) 368 (98.1) 0.174
Yes 166 (4.0) 7 (1.8) 13 (3.5) 7 (1.9)
Anastomosis
No 4105 (98.4) 394 (98.3) 0.774 367 (97.9) 368 (98.1) 0.794
Yes 65 (1.6) 7 (1.8) 8 (2.1) 7 (1.9)
Cardiovascular
No 3814 (91.5) 376 (93.8) 0.111 346 (92.3) 352 (93.9) 0.388
Yes 356 (8.5) 25 (6.2) 29 (7.7) 23 (6.1)
Colostomy complications
No 4133 (99.1) 401 (100) 0.072 > 369 (> 98.4)a 375 (100) 0.062
Yes 37 (0.9) 0 (0) a 0 (0)
Respiratory
No 3853 (92.4) > 395 (> 98.5)a < 0.001 347 (92.5) > 369 (98.4)a < 0.001
Yes 317 (7.6) a 28 (7.47) a
Sepsis
No 3890 (93.3) 386 (96.3) 0.021 353 (94.1) 361 (96.3) 0.172
Yes 280 (6.7) 15 (3.7) 22 (5.9) 14 (3.7)
Thrombosis
No 4077 (97.8) > 395 (> 98.5)a 0.044 367 (97.9) > 369 (> 98.4)a 0.223
Yes 93 (2.2) a 8 (2.1) a
Wound disruption
No 4063 (97.4) > 395 (> 98.5)a 0.017 367 (97.9) > 369 (> 98.4)a 0.223
Yes 107 (2.6) a 8 (2.1) a
a Indicates that the figure is < 6. If a single figure is censured another will bemarked as B>^ reflecting a value up to
5 points higher than that stated, to ensure the censured figure cannot be calculated
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trial data demonstrates comparable technical success of stent
insertion to the present study. However, the pragmatic nature
of the current study, including all subjects undergoing bridg-
ing stenting, provides a different subject cohort to that seen in
clinical trials. Local provider and clinical trial data demon-
strated good correlation with study data in the present study,
supporting the validity of case identification and the results
reported.
The coding of technical failure of colorectalMS insertion is
challenging, as there is no nationally recognised nomenclature
for how to code this and the same code as a successful stent
may be employed. It was also not possible to discern between
radiologic and endoscopic stent placement. Therefore, a pro-
cedural success rate for colorectal MS insertion cannot be
accurately calculated. However, the close correlation between
the number of subjects assumed to have failed MS insertion,
as they required immediate resection, to the reported CREST,
2004 meta-analysis and 2014 meta-analysis MS insertion pro-
cedural success rates suggests this is a reasonable proxy for
technical stent insertion failure.
In this, the largest study to date of colorectal MS as a bridge
to surgery, compared with emergency surgery, a significant re-
duction in mortality for those undergoing MS was observed.
Subjects undergoingMS insertion also had lower stoma rates, a
higher incidence of laparoscopic surgery and a lower incidence
of respiratory complications. Our study supports the hypothesis
that bridging colorectal MS for subjects presenting with bowel
obstruction are of benefit to patients, by potentially avoiding
high-risk emergency surgery. Prospective randomised studies
should focus on the opportunities provided by MS to optimise
subjects prior to eventual curative resection.
Data are presented as median (IQR) or n (%)
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